McManus DD, Rienstra M, Benjamin EJ (2012) An update on the prognosis of patients with atrial fibrillation. Circulation 126:e143–e146

Article  PubMed  PubMed Central  Google Scholar 

Amin A, Houmsse A, Ishola A, Tyler J, Houmsse M (2016) The current approach of atrial fibrillation management. Avicenna J Med 6:8–16

Article  PubMed  PubMed Central  Google Scholar 

Markides V, Schilling RJ (2003) Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. Heart 89:939–943

Article  PubMed  PubMed Central  Google Scholar 

Nesheiwat Z, Goyal A, Jagtap M (2022) Atrial fibrillation. StatPearls Publishing, Treasure Island

Google Scholar 

Roshdy HS, Naguib TA, Elthalawi MA (2016) A new score for detection of early cardioversion using intravenous amiodarone in recent onset atrial fibrillation. Egpt Heart J 68:245–252

Article  Google Scholar 

Kapadia M, Jagadish PS, Hutchinson M, Lee H (2023) Atrial fibrillation, electroconvulsive therapy, stroke risk, and anticoagulation. Springer Science and Business Media, Deutschland GmbH

Book  Google Scholar 

Arrigo M, Jeger N, Seifert B, Spahn DR, Bettex D, Rudiger A (2015) Disappointing success of electrical cardioversion for new-onset atrial fibrillation in cardiosurgical ICU patients. Intensive Care Medicine Experimental, SpringerOpen

Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al (2023) ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology/American Heart association joint committee on clinical practice guidelines. Circulation. Lippincott Williams and Wilkins 2024. pp E1–156

Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J et al (2022) 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 43:561–632

Article  PubMed  Google Scholar 

Lippi G, Sanchis-Gomar F, Cervellin G (2021) Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke 16:217–221

Article  PubMed  Google Scholar 

Peters SAE, Woodward M (2019) Established and novel risk factors for atrial fibrillation in women compared with men. Heart 105:226–234

Article  CAS  PubMed  Google Scholar 

Choi Y-J, Choi E-K, Han K-D, Jung J-H, Park J, Lee E et al (2018) Temporal trends of the prevalence and incidence of atrial fibrillation and stroke among Asian patients with hypertrophic cardiomyopathy: a nationwide population-based study. Int J Cardiol 273:130–135

Article  PubMed  Google Scholar 

Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ et al (2014) Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 129:837–847

Article  PubMed  Google Scholar 

Schäfer A, Flierl U, Berliner D, Bauersachs J (2020) Anticoagulants for stroke prevention in atrial fibrillation in elderly patients. Cardiovasc Drugs Ther 34:555–568

Article  PubMed  PubMed Central  Google Scholar 

Bai CJ, Madan N, Alshahrani S, Aggarwal NT, Volgman AS (2018) Sex differences in atrial fibrillation-update on risk assessment, treatment, and long-term risk. Curr Treat Options Cardiovasc Med 20:79

Article  PubMed  Google Scholar 

Laäs DJ, Naidoo M (2018) Oral anticoagulants and atrial fibrillation: a South African perspective. S Afr Med J 108:640–646

Article  PubMed  Google Scholar 

Tellor KB, Patel S, Armbruster AL, Daly MW (2015) Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital. J Clin Pharm Ther 40:447–451

Article  CAS  PubMed  Google Scholar 

Armbruster AL, Buehler KS, Min SH, Riley M, Daly MW (2014) Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting. Am Health Drug Benefits 7:376–384

PubMed  PubMed Central  Google Scholar 

Eyileten C, Postula M, Jakubik D, Toma A, Mirowska-Guzel D, Patti G, Renda G, Siller-Matula JM (2020) Non-vitamin K oral anticoagulants (Noac) versus vitamin K antagonists (vka) for atrial fibrillation with elective or urgent percutaneous coronary intervention: a meta-analysis with a particular focus on combination type. J Clin Med 9(4):1120

Article  CAS  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA et al (2020) statement: an updated guideline for reporting systematic reviews. Int J Surg 2021:88

Google Scholar 

Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M (2014) Newcastle–Ottawa quality assessment scale cohort studies. University of Ottawa, Ottawa

Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. The BMJ 366

The cochrane collaboration. Review manager (RevMan) version 5.4 [Internet]. 2020 [cited 2024 Apr 13]. Available from: https://training.cochrane.org/System/Files/Uploads/Protected_file/RevMan5.4_user_guide.Pdf

Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M et al (2015) Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: Findings From the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (Aristotle) trial. Circulation 132:624–632

Article  CAS  PubMed  Google Scholar 

Chaudhry UA, Ezekowitz MD, Gracely EJ, George WT, Wolfe CM, Harper G et al (2021) Comparison of low-dose direct acting anticoagulant and Warfarin in patients aged ≥80 years with atrial fibrillation. Am J Cardiol 152:69–77

Article  CAS  PubMed  Google Scholar 

Reinecke H, Nabauer M, Gerth A, Limbourg T, Treszl A, Engelbertz C et al (2015) Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. Kidney Int 87:200–209

Article  CAS  PubMed  Google Scholar 

Patti G, Cavallari I, Hanon O, De Caterina R (2018) The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly. Int J Cardiol 265:118–124

Article  PubMed  Google Scholar 

Kanai Y, Oguro H, Tahara N, Matsuda H, Takayoshi H, Mitaki S et al (2018) Analysis of recurrent stroke volume and prognosis between warfarin and four non-vitamin K antagonist oral anticoagulants’ administration for secondary prevention of stroke. J Stroke Cerebrovasc Dis 27:338–345

Article  PubMed  Google Scholar 

Kim M, You SC, Sung J-H, Jang E, Yu HT, Kim T-H et al (2021) Safety and long-term outcomes of catheter ablation according to sex in patients with atrial fibrillation: a nationwide cohort study. Int J Cardiol 338:95–101

Article  PubMed  Google Scholar 

Okumura K, Lip GYH, Akao M, Tanizawa K, Fukuzawa M, Abe K et al (2017) Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: rationale and design of the ELDERCARE-AF study. Am Heart J 194:99–106

Article  CAS  PubMed  Google Scholar 

Melgaard L, Overvad TF, Jensen M, Christensen TD, Lip GY, Larsen TB, Nielsen PB (2021) Effectiveness and safety of noac versus warfarin in patients with atrial fibrillation and aortic stenosis. J Am Heart Assoc 10(23):e022628

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strange JE, Sindet-Pedersen C, Staerk L, Grove EL, Gerds TA, Torp-Pedersen C, Gislason GH, Olesen JB (2021) All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease. Eur Heart J-Cardiovasc Pharmacother 7(FI1):f93-100. https://doi.org/10.1093/ehjcvp/pvaa011/5739442

Article  PubMed  Google Scholar 

Li W, Wang S, Li S, Chen X, Xiong Y (2019) Clinical outcomes of valvular versus nonvalvular atrial fibrillation in acute anterior circulation occlusive stroke undergoing endovascular treatment. J Stroke Cerebrovasc Dis 28:31–37

Article  PubMed  Google Scholar 

Clemens A, Noack H, Brueckmann M, Lip GYH (2014) Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria. PLoS ONE 9:1–8

Article  Google Scholar 

Fanaroff AC, Vora AN, Lopes RD (2022) Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease. Eur Heart J Suppl 24:A19-31

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hohnloser SH, Lopes RD (2014) Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention. Eur Heart J 35(47):3323–3325

Article  CAS  PubMed  Google Scholar 

Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy